study to evaluate the safety and efficacy of xav-19 in patients with covid-19 induced moderate pneumonia

Conditions: SARS Virus

Summary: early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is a very promising therapeutic approach. polyclonal neutralizing antibodies offers many advantages such as providing immediate immunity, consequently blunt an early pro-inflammatory pathogenic endogenous antibody response and lack of drug-drug interactions1-3. because a suboptimal endogenous early antibody response with regard to sars-cov-2 replication in severe cases is observed, neutralising antibody treatment can be very interesting for patient with covid-19 induced moderate pneumonia4,5. convalescent plasma to treat infected patients is therefore an interesting therapeutic option currently under evaluation. however, the difficulties of collecting plasma and its safety aspects are not adapted to many patients. a new polyclonal humanized anti-sars-cov2 antibodies (xav-19) is being developed by xenothera, which can be administered as intravenous treatment. xav-19 is a heterologous swine glyco-humanized polyclonal antibody (gh-pab) raised against the spike protein of sars-cov-2, inhibiting infection of ace-2 positive human cells with sars-cov-2. pharmacokinetic and pharmacodynamic studies have been performed in preclinical models including primates and a first in human study with another fully representative gh-pab from xenothera is ongoing in volunteer patients recipients of a kidney graft. these studies indicated that 5 consecutive administrations of gh-pabs can be safely performed in humans. the objective of this 2-steps phase 2 randomized double-blind, placebo-controlled study is 1) to define the optimal and safety xav-19 dose to administrate in patients with covid-19 induced moderate pneumonia ; 2) to show the clinical benefit of selected dose of xav-19 when administered to patients with covid-19 induced moderate pneumonia.

for the first set of statistical analyses, to allow early reporting of primary and secondary endpoints at d15, the blind will be partially broken once all patients have completed day 29. except for statisticians, only the principal investigator and the scientific coordinator will have access to the full data set for the analysis of the primary and secondary endpoints up to day 29. the database will be partially locked (with all data up to day 29) as neither monitors nor investigators will be informed of the unblinding until the final data for day 60 is completed and the final database is locked.

Eligibility criteria:
phase 2a: inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures 2. male or female ≥ 18 years and ≤ 85 years 3. hospitalized for covid-19 4. positive sars-cov-2 rt-pcr in any body specimen (nasopharynx, saliva, sputum) ≤ 10 days before enrolment 5. evidence of pulmonary involvement (on lung examination \[rales/crackles\] and/or chest-imaging \[chest x-ray or computed tomography\]) 6. requiring o2 supplement ≤ 6l/min at screening 7. requiring o2 supplementation with spo2 ≥ 94% on o2 therapy at screening 8. first onset of covid-19 symptoms ≤ 10 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, whichever as occurred fist 9. wocbp must have a negative urinary pregnancy test the day of inclusion 10. all sexually active male subjects must agree to use an adequate method of contraception throughout the study period and for 90 days after the last dose of study drug and agree to no sperm donation until the end of the study, or for 90 days after the last dose of xav-19, whichever is longer 11. patients with french social security exclusion criteria: 1. evidence of multiorgan failure (severe covid-19) 2. mechanically ventilated (including ecmo) 3. receipt of immunoglobulins or any blood products in the past 30 days 4. psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the investigator, would affect subject safety and/or compliance 5. end-stage renal disease (egfr \< 15 ml/min/1,73 m2) 6. child-pugh c stage liver cirrhosis 7. decompensated cardiac insufficiency 8. history of active drug abuse 9. known allergy, hypersensitivity, or intolerance to the study drug, or to any of its components 10. females of childbearing potential without contraceptive method, or with positive pregnancy test, breastfeeding, or planning to become pregnant during the study period 11. current documented and uncontrolled bacterial infection. 12. prior severe (grade 3) allergic reactions to plasma transfusion 13. patient participating in another interventional clinical trial 14. life expectancy estimated to be less than 6 months 15. patient under guardianship or trusteeship phase 2b: inclusion criteria: 1. willing and able to provide written informed consent prior to performing study procedures 2. male or female ≥ 18 years 3. hospitalized for covid-19 4. documentation of sars-cov-2 infection before enrolment, by positive sars-cov-2 rt-pcr or antigen in any body specimen (nasopharynx, oropharynx, saliva, sputum, bronchoalveolar lavage ...) before enrolment 5. evidence of pulmonary involvement (on lung examination \[rales/crackles\] and/or chestimaging \[chest x-ray or computed tomography\]) 6. requiring o2 supplement ≤ 6l/min at screening 7. requiring o2 supplementation with spo2 ≥ 92% on o2 therapy at screening (or ≥ 90 % if chronic obstructive pulmonary disease) 8. first onset of covid-19 symptoms ≤ 14 days, among fever and/or chills, headache, myalgias, cough, shortness of breath, whichever as occurred fist (other symptoms such as asthenia not to be considered in this list) 9. wocbp must have a negative urinary pregnancy test the day of inclusion 10. all sexually active male subjects must agree to use an adequate method of contraception throughout the study period and for 90 days after the last dose of study drug and agree to no sperm donation until the end of the study, or for 90 days after the last dose of xav-19, whichever is longer 11. patients with french social security exclusion criteria: 1. evidence of multiorgan failure (severe covid-19) 2. mechanically ventilated (including ecmo) 3. receipt of immunoglobulins or any blood products in the past 30 days 4. psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the investigator, would affect subject safety and/or compliance 5. end-stage renal disease (egfr \< 15 ml/min/1,73 m2) 6. child-pugh c stage liver cirrhosis 7. decompensated cardiac insufficiency 8. known allergy, hypersensitivity, or intolerance to the study drug, or to any of its components 9. females of childbearing potential without contraceptive method, or with positive pregnancy test, breastfeeding, or planning to become pregnant during the study period 10. current documented and uncontrolled bacterial infection. 11. prior severe (grade 3) allergic reactions to plasma transfusion 12. patient participating in another interventional clinical trial 13. life expectancy estimated to be less than 6 months 14. patient under guardianship or trusteeship 15. patient already included 16. prior hospitalisation in intensive care unit for the current covid-19 episode

Keywords: sars-cov-2 covid-19 moderate pneumonia antibody